Last reviewed · How we verify

DCR-PHXC — Competitive Intelligence Brief

DCR-PHXC (DCR-PHXC) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: RNA interference therapeutic. Area: Genetic/Metabolic Disease.

phase 3 RNA interference therapeutic PHXC mRNA Genetic/Metabolic Disease Small molecule Live · refreshed every 30 min

Target snapshot

DCR-PHXC (DCR-PHXC) — Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. DCR-PHXC is an RNA interference therapeutic that silences the PHXC gene to reduce production of a disease-causing protein.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DCR-PHXC TARGET DCR-PHXC Dicerna Pharmaceuticals, Inc., a Novo Nordisk company phase 3 RNA interference therapeutic PHXC mRNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (RNA interference therapeutic class)

  1. Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DCR-PHXC — Competitive Intelligence Brief. https://druglandscape.com/ci/dcr-phxc. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: